The involvement of tachykinins in the airway reactivity of ovalbumin (OA)-sensitized rats was studied by capsaicin (CAPS) treatment. In subcutaneously sensitized animals, the reactivity to both OA aerosol and serotonin given intravenously was decreased when CAPS was given after the sensitization period. No effects on the serum IgE and IgG antibody levels were seen in these animals. In contrast, when CAPS was given before the sensitization period, no effects were seen on the OA aerosol and serotonin reactivities. Immunohistochemical examination revealed that the la antigen expression in the bronchial epithelium was increased by both subcutaneous and aerosol sensitization. The CAPS treatment decreased this la antigen expression. Histological examination of mononuclear cells, mast cells and goblet cells revealed only small effects on the cell numbers by both the OA sensitization and the CAPS treatment. The results demonstrate a link between tachykinins, serotonin, the immune system and clinical lung reactivity. The mechanisms for this seem to be complex, since the timing of the CAPS treatment and antigen sensitization is crucial for the outcome.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.